Suppr超能文献

接受体外膜肺氧合治疗的新生儿的万古霉素药代动力学。

Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation.

作者信息

Buck M L

机构信息

Department of Pharmacy, Children's Medical Center, School of Medicine, University of Virginia, Charlottesville, USA.

出版信息

Pharmacotherapy. 1998 Sep-Oct;18(5):1082-6.

PMID:9758319
Abstract

Vancomycin is administered as both prophylaxis and treatment in neonates receiving extracorporeal membrane oxygenation (ECMO), typically after surgery. An open-label, retrospective study was conducted to determine dosing strategies in all neonates who received vancomycin during ECMO and compare pharmacokinetic values with those of matched controls not receiving ECMO. Fifteen neonates receiving ECMO were given vancomycin infused into the circuit, with dosages based on weight and gestational age. Blood for serum concentrations was drawn around the third dose, for trough concentrations immediately before the dose, and for peak concentrations 1 hour after infusion. Samples were analyzed by fluorescence polarization immunoassay. The most frequent regimen for both groups (8 ECMO, 13 controls) was 10 mg/kg every 8 hours. It produced peak and trough concentrations of 27.5 +/- 4.3 and 13.7 +/- 2.7 microg/ml, and 23.0 +/- 5.4 and 13.2 +/- 4.5 microg/ml, respectively. Pharmacokinetic analysis using a one-compartment model revealed volume of distribution of 0.45 +/- 0.18 L/kg, half-life of 8.29 +/- 2.23 hours, and total body clearance of 0.65 +/- 0.28 ml/min/kg in ECMO recipients. Volume of distribution and clearance were not significantly different in controls (0.39 +/- 0.12 L/kg, 0.79 +/- 0.41 ml/min/kg), but half-life was shorter (6.53 +/- 2.05 hrs, p = 0.02). Based on long volume of distribution in neonates receiving ECMO, we recommend that empiric vancomycin regimens incorporate a longer dosing interval than the 6-8 hours commonly recommended for term infants. The effects of severity of illness on drug elimination require additional study.

摘要

在接受体外膜肺氧合(ECMO)治疗的新生儿中,通常在术后使用万古霉素进行预防和治疗。开展了一项开放性回顾性研究,以确定所有在ECMO治疗期间接受万古霉素治疗的新生儿的给药策略,并将药代动力学值与未接受ECMO治疗的匹配对照组进行比较。15名接受ECMO治疗的新生儿在体外循环回路中输注万古霉素,剂量根据体重和胎龄确定。在第三次给药前后采集血样测定血清浓度,给药前即刻测定谷浓度,输注后1小时测定峰浓度。样本采用荧光偏振免疫分析法进行分析。两组(8名接受ECMO治疗的新生儿、13名对照组新生儿)最常用的给药方案均为每8小时10mg/kg。该方案产生的峰浓度和谷浓度在接受ECMO治疗的新生儿中分别为27.5±4.3和13.7±2.7μg/ml,在对照组中分别为23.0±5.4和13.2±4.5μg/ml。采用单室模型进行的药代动力学分析显示,接受ECMO治疗的新生儿的分布容积为0.45±0.18L/kg,半衰期为8.29±2.23小时,全身清除率为0.65±0.28ml/min/kg。对照组的分布容积和清除率无显著差异(分别为0.39±0.12L/kg和0.79±0.41ml/min/kg),但半衰期较短(6.53±2.05小时,p=0.02)。基于接受ECMO治疗的新生儿分布容积较大,我们建议经验性万古霉素治疗方案的给药间隔应长于足月儿通常推荐的6-8小时。疾病严重程度对药物消除的影响需要进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验